Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 16/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.61 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210996 | 0.88 | GRIN1 (0.58) | GRIN1GRIN2BNPBWR1 | |
| SCHEMBL33526059 | 0.84 | GRIN1 (0.55) | GRIN1GRIN2B | |
| SCHEMBL2598348 | 0.82 | GRIN1 (0.55) | GRIN1GRIN2BNPBWR1MCHR1 | |
| SCHEMBL17754814 | 0.81 | GRIN1 (0.63) | GRIN1GRIN2B | |
| SCHEMBL23210919 | 0.79 | GRIN1 (0.49) | GRIN1GRIN2BNPBWR1MCHR1 | |
| SCHEMBL30308758 | 0.79 | GRIN1 (0.49) | GRIN1GRIN2BNPBWR1MCHR1 | |
| SCHEMBL22775009 | 0.77 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL29525058 | 0.77 | GRIN1 (0.98) | GRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL22775310 | 0.77 | GRIN1 (0.98) | GRIN1GRIN2B | |
| SCHEMBL22892720 | 0.76 | NPBWR1 (0.51) | GRIN1GRIN2BNPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885NPBWR1 3434/4885 |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885NPBWR1 3434/4885 |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885NPBWR1 3434/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885NPBWR1 3434/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885NPBWR1 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.